Development of 3D-iNET ORION: a novel, pre-clinical, three-dimensional in vitro cell model for modeling human metastatic neuroendocrine tumor of the pancreas.
3D cancer cell lines
Neuroendocrine tumor
Pancreas
Journal
Human cell
ISSN: 1749-0774
Titre abrégé: Hum Cell
Pays: Japan
ID NLM: 8912329
Informations de publication
Date de publication:
05 Aug 2024
05 Aug 2024
Historique:
received:
19
01
2024
accepted:
08
07
2024
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
5
8
2024
Statut:
aheadofprint
Résumé
Neuroendocrine tumors (NETs) of the pancreas are rare neoplasms that present complex challenges to diagnosis and treatment due to their indolent course. The incidence of pancreatic neuroendocrine tumors has increased significantly over the past two decades. A limited number of pancreatic neuroendocrine cell lines are currently available for the research. Here, we present 3D-iNET ORION, a novel 3-dimensional (spheroid) cell line, isolated from human pancreatic neuroendocrine tumor liver metastasis. Three-dimensionally grown (3D) cancer cell lines have gained interest over the past years as 3D cancer cell lines better recapitulate the in vivo structure of tumors, and are more suitable for in vitro and in vivo experiments. 3D-iNET ORION cancer cell line showed high potential to form tumorspheres when embedded in Matrigel matrix and expresses synaptophysin and EpCAM. Electron microscopy analysis of cancer cell line proved the presence of dense neurosecretory granules. When xenografted into athymic mice, 3D-iNET ORION cells produce slow-growing tumors, positive for chromogranin and synaptophysin. Human Core Exome Panel Analysis has shown that 3DiNET ORION cell line retains the genetic aberration profile detected in the original tumor. In conclusion, our newly developed neuroendocrine cancer cell line can be considered as a new research tool for in vitro and in vivo experiments.
Identifiants
pubmed: 39103560
doi: 10.1007/s13577-024-01113-7
pii: 10.1007/s13577-024-01113-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agentúra na Podporu Výskumu a Vývoja
ID : APVV-21-0372
Organisme : NCI NIH HHS
ID : R01 CA256973
Pays : United States
Organisme : NIH (US)
ID : NIH SC1GM121182
Organisme : European Regional Development Fund
ID : ITMS: 313011AFG5
Informations de copyright
© 2024. The Author(s).
Références
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54. https://doi.org/10.1007/s12022-022-09708-2 .
doi: 10.1007/s12022-022-09708-2
pubmed: 35294740
Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (New York, NY). 2017;19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002 .
doi: 10.1016/j.neo.2017.09.002
pubmed: 29091800
Clift AK, Kidd M, Bodei L, Toumpanakis C, Baum RP, Oberg K, et al. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology. 2020;110(6):444–76. https://doi.org/10.1159/000503721 .
doi: 10.1159/000503721
pubmed: 31557758
Chen M, Van Ness M, Guo Y, Gregg J. Molecular pathology of pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2012;3(3):182–8. https://doi.org/10.3978/j.issn.2078-6891.2012.018 .
doi: 10.3978/j.issn.2078-6891.2012.018
pubmed: 22943010
pmcid: 3418536
Chung C. Management of neuroendocrine tumors. Am J Health-Syst Pharm : AJHP : Off J Am Soc Health-Syst Pharm. 2016;73(21):1729–44. https://doi.org/10.2146/ajhp150373 .
doi: 10.2146/ajhp150373
Hori T, Takaori K, Uemoto S. Pancreatic neuroendocrine tumor accompanied with multiple liver metastases. World J Hepatol. 2014;6(8):596–600. https://doi.org/10.4254/wjh.v6.i8.596 .
doi: 10.4254/wjh.v6.i8.596
pubmed: 25232452
pmcid: 4163742
Jubelin C, Muñoz-Garcia J, Griscom L, Cochonneau D, Ollivier E, Heymann, et al. Three-dimensional in vitro culture models in oncology research. Cell Biosci. 2022;12(1):155. https://doi.org/10.1186/s13578-022-00887-3 .
doi: 10.1186/s13578-022-00887-3
pubmed: 36089610
pmcid: 9465969
Yamasaki AE, Warshaw JN, Kyalwazi BL, Matsui H, Jepsen K, Panopoulos AD. An iPSC line derived from a human acute myeloid leukemia cell line (HL-60-iPSC) retains leukemic abnormalities and displays myeloid differentiation defects. Stem cell research. 2020;49: 102096. https://doi.org/10.1016/j.scr.2020.102096 .
doi: 10.1016/j.scr.2020.102096
pubmed: 33370871
pmcid: 8031422
Grozinsky-Glasberg S, Shimon I, Rubinfeld H. The role of cell lines in the study of neuroendocrine tumors. Neuroendocrinology. 2012;96(3):173–87. https://doi.org/10.1159/000338793 .
doi: 10.1159/000338793
pubmed: 22538498
Ney A, Canciani G, Hsuan JJ, Pereira SP. Modelling pancreatic neuroendocrine cancer: from bench side to clinic. Cancers. 2020;12(11):3170. https://doi.org/10.3390/cancers12113170 .
doi: 10.3390/cancers12113170
pubmed: 33126717
pmcid: 7693644
Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207–18. https://doi.org/10.1089/adt.2014.573 .
doi: 10.1089/adt.2014.573
pubmed: 24831787
pmcid: 4026212
Grönholm M, Feodoroff M, Antignani G, Martins B, Hamdan F, Cerullo V. Patient-derived organoids for precision cancer immunotherapy. Can Res. 2021;81(12):3149–55. https://doi.org/10.1158/0008-5472.CAN-20-4026 .
doi: 10.1158/0008-5472.CAN-20-4026
Malosio ML, Giordano T, Laslop A, Meldolesi J. Dense-core granules: a specific hallmark of the neuronal/neurosecretory cell phenotype. J Cell Sci. 2004;117(Pt 5):743–9. https://doi.org/10.1242/jcs.00934 .
doi: 10.1242/jcs.00934
pubmed: 14734658
Fendrich V, Waldmann J, Esni F, Ramaswamy A, Mullendore M, Buchholz M, et al. Snail and sonic hedgehog activation in neuroendocrine tumors of the ileum. Endocr Relat Cancer. 2007;14(3):865–74. https://doi.org/10.1677/ERC-07-0108 .
doi: 10.1677/ERC-07-0108
pubmed: 17914115
Galván JA, Astudillo A, Vallina A, Fonseca PJ, Gómez-Izquierdo L, García-Carbonero R, et al. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol. 2013;140(1):61–72. https://doi.org/10.1309/AJCPIV40ISTBXRAX .
doi: 10.1309/AJCPIV40ISTBXRAX
pubmed: 23765535
Karafin MS, Cummings CT, Fu B, Iacobuzio-Donahue CA. The developmental transcription factor Gata4 is overexpressed in pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol. 2009;3(1):47–55.
pubmed: 19918328
Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Can Res. 2010;70(5):2115–25. https://doi.org/10.1158/0008-5472.CAN-09-2979 .
doi: 10.1158/0008-5472.CAN-09-2979
Eisinger-Mathason TS, Simon MC. HIF-1alpha partners with FoxA2, a neuroendocrine-specific transcription factor, to promote tumorigenesis. Cancer Cell. 2010;18(1):3–4. https://doi.org/10.1016/j.ccr.2010.06.007 .
doi: 10.1016/j.ccr.2010.06.007
pubmed: 20609346
pmcid: 3144028
Park JW, Lee JK, Witte ON, Huang J. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod Pathol. 2017;30(9):1262–72. https://doi.org/10.1038/modpathol.2017.44 .
doi: 10.1038/modpathol.2017.44
pubmed: 28621319
pmcid: 6330177
Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol : AIMM. 2010;18(1):55–61. https://doi.org/10.1097/PAI.0b013e3181b16b88 .
doi: 10.1097/PAI.0b013e3181b16b88
pubmed: 19661786
Zhu X, Wang X, Gong Y, Deng J. E-cadherin on epithelial-mesenchymal transition in thyroid cancer. Cancer Cell Int. 2021;21(1):695. https://doi.org/10.1186/s12935-021-02344-6 .
doi: 10.1186/s12935-021-02344-6
pubmed: 34930256
pmcid: 8690896
Krieg A, Mersch S, Boeck I, Dizdar L, Weihe E, Hilal Z, et al. New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines. PLoS One. 2014;9(2): e88713. https://doi.org/10.1371/journal.pone.0088713 .
doi: 10.1371/journal.pone.0088713
pubmed: 24551139
pmcid: 3925161
Strnadel J, Woo SM, Choi S, Wang H, Grendar M, Fujimura K. 3D culture protocol for testing gene knockdown efficiency and cell line derivation. Bio Protocol. 2018. https://doi.org/10.21769/BioProtoc.2874 .
doi: 10.21769/BioProtoc.2874
pubmed: 34285988
pmcid: 8275222